Intellipharmaceutics to Present at the 25th Annual Piper Jaffray Healthcare Conference
December 02, 2013 07:00 ET
|
Intellipharmaceutics International Inc.
TORONTO, Dec. 2, 2013 (GLOBE NEWSWIRE) -- Intellipharmaceutics International Inc. (Nasdaq:IPCI) (TSX:I), a pharmaceutical company specializing in the research, development and manufacture of novel and...
Intellipharmaceutics Announces At-The-Market Offering of Common Shares
November 27, 2013 16:30 ET
|
Intellipharmaceutics International Inc.
TORONTO, Nov. 27, 2013 (GLOBE NEWSWIRE) -- Intellipharmaceutics International Inc. (Nasdaq:IPCI) (TSX:I), a pharmaceutical company specializing in the research, development and manufacture of novel...
Intellipharmaceutics / Par to Make Immediate Commercial Launch of 15 and 30 mg Generic Focalin XR(R)
November 18, 2013 16:34 ET
|
Intellipharmaceutics International Inc.
– FDA Issues Final Approval of 15 mg, With 180 Days of Exclusivity, and 30 mg; and
– Tentative Approvals for the Company's 5, 10, 20 and 40 mg Strengths
TORONTO, Nov. 18, 2013...
Intellipharmaceutics Announces Third Quarter 2013 Results
October 01, 2013 17:00 ET
|
Intellipharmaceutics International Inc.
TORONTO, Oct. 1, 2013 (GLOBE NEWSWIRE) -- Intellipharmaceutics International Inc. (Nasdaq:IPCI) (TSX:I), a pharmaceutical company specializing in the research, development and manufacture of novel and...
Intellipharmaceutics Closes Public Offering for US$3.1 Million
July 31, 2013 17:25 ET
|
Intellipharmaceutics International Inc.
TORONTO, July 31, 2013 (GLOBE NEWSWIRE) -- Intellipharmaceutics International Inc. (Nasdaq:IPCI) (TSX:I), a pharmaceutical company specializing in the research, development and manufacture of novel...
Intellipharmaceutics Announces Pricing of Public Offering of Common Shares and Warrants
July 26, 2013 09:29 ET
|
Intellipharmaceutics International Inc.
TORONTO, July 26, 2013 (GLOBE NEWSWIRE) -- Intellipharmaceutics International Inc. (Nasdaq:IPCI) (TSX:I), a pharmaceutical company specializing in the research, development and manufacture of novel...
Intellipharmaceutics Announces Proposed Public Offering of Units of Common Shares and Warrants
July 26, 2013 02:06 ET
|
Intellipharmaceutics International Inc.
TORONTO, July 26, 2013 (GLOBE NEWSWIRE) -- Intellipharmaceutics International Inc. (Nasdaq:IPCI) (TSX:I), a pharmaceutical company specializing in the research, development and manufacture of novel...
Intellipharmaceutics Updates Developments on Its Rexista(TM) Oxycodone Technology
July 15, 2013 07:00 ET
|
Intellipharmaceutics International Inc.
TORONTO, July 15, 2013 (GLOBE NEWSWIRE) -- Intellipharmaceutics International Inc. (Nasdaq:IPCI) (TSX:I), a pharmaceutical company specializing in the research, development and manufacture of novel...
Intellipharmaceutics Announces Second Quarter 2013 Results
July 02, 2013 18:00 ET
|
Intellipharmaceutics International Inc.
TORONTO, July 2, 2013 (GLOBE NEWSWIRE) -- Intellipharmaceutics International Inc. (Nasdaq:IPCI) (TSX:I), a pharmaceutical company specializing in the research, development and manufacture of novel and...
Intellipharmaceutics Announces Webcast of Presentation at the 12th Annual Needham Healthcare Conference
April 24, 2013 17:00 ET
|
Intellipharmaceutics International Inc.
TORONTO, April 24, 2013 (GLOBE NEWSWIRE) -- Intellipharmaceutics International Inc. (Nasdaq:IPCI) (TSX:I), a pharmaceutical company specializing in the research, development and manufacture of novel...